Cubist Systematic Strategies’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-32,834
Closed -$2.24M 4984
2022
Q3
$2.24M Sell
32,834
-29,655
-47% -$1.64M 0.01% 1890
2022
Q2
$2M Buy
62,489
+51,598
+474% +$1.51M 0.01% 1869
2022
Q1
$377K Sell
10,891
-26,899
-71% -$804K ﹤0.01% 2703
2021
Q4
$1.11M Sell
37,790
-140,009
-79% -$4.34M 0.01% 1842
2021
Q3
$4.53M Buy
177,799
+92,896
+109% +$2.73M 0.06% 515
2021
Q2
$2.97M Buy
84,903
+7,269
+9% +$284K 0.03% 836
2021
Q1
$3.16M Buy
77,634
+23,095
+42% +$1.06M 0.04% 714
2020
Q4
$2.36M Buy
54,539
+21,347
+64% +$1.05M 0.03% 845
2020
Q3
$1.83M Sell
33,192
-18,295
-36% -$1.16M 0.03% 965
2020
Q2
$3.25M Buy
51,487
+32,906
+177% +$2.26M 0.06% 539
2020
Q1
$949K Sell
18,581
-4,668
-20% -$313K 0.03% 869
2019
Q4
$1.85M Buy
23,249
+10,144
+77% +$601K 0.03% 794
2019
Q3
$636K Sell
13,105
-4,257
-25% -$222K 0.01% 1179
2019
Q2
$913K Buy
+17,362
New +$998K 0.02% 1099
2018
Q4
Sell
-9,410
Closed -$358K 2349
2018
Q3
$358K Buy
9,410
+1,308
+16% +$57.9K 0.02% 1048
2018
Q2
$366K Buy
+8,102
New +$369K 0.02% 960
2018
Q1
Sell
-733
Closed -$29K 2143
2017
Q4
$29K Sell
733
-5,786
-89% -$216K ﹤0.01% 1823
2017
Q3
$202K Sell
6,519
-1,686
-21% -$47.4K 0.01% 1439
2017
Q2
$224K Buy
8,205
+3,991
+95% +$119K 0.01% 1223
2017
Q1
$155K Buy
+4,214
New +$106K 0.01% 1278
2016
Q2
Sell
-5,665
Closed -$90K 1937
2016
Q1
$90K Buy
+5,665
New +$101K 0.01% 1412

Other funds holding GBT

Cubist Systematic Strategies's GBT Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 32,834 shares — an estimated $2.24M sold.

Cubist Systematic Strategies first reported a position in GBT in Q1 2016 and held it in 21 quarters. The position peaked at $4.53M in Q3 2021. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Cubist Systematic Strategies reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 32,834 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $2.24M.
  • Cubist Systematic Strategies first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 21 quarters.
  • Cubist Systematic Strategies's Global Blood Therapeutics, Inc. position peaked at $4.53M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.